MetLife Investment Management’s Perspective Therapeutics CATX Stock Holding History

MetLife Investment Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$138K	Buy	33,079 +16,362	+98%	+$69.1K	﹤0.01%	2395
2025 Q4	$46K	Sell	16,717 -12,842	-43%	-$36.6K	﹤0.01%	2733
2025 Q3	$101K	Sell	29,559 -1,994	-6%	-$7.27K	﹤0.01%	2644
2025 Q2	$109K	Buy	31,553 +243	+0.8%	+$642	﹤0.01%	2503
2025 Q1	$66.7K	Buy	31,310 +9,082	+41%	+$27.3K	﹤0.01%	2658
2024 Q4	$70.9K	Sell	22,228 -8,937	-29%	-$73K	﹤0.01%	2708
2024 Q3	$416K	Buy	31,165 +19,137	+159%	+$255K	﹤0.01%	1880
2024 Q2	$120K	Buy	+12,028	New	+$174K	﹤0.01%	2513

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's CATX Position: Q1 2026 in Review

MetLife Investment Management increased its Perspective Therapeutics (CATX) stake by 98% in Q1 2026, buying an estimated $69.1K and bringing the position to 33,079 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

MetLife Investment Management first reported a position in CATX in Q2 2024 and has held it in 8 quarters since. The position peaked at $416K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

MetLife Investment Management held 33,079 shares of Perspective Therapeutics worth $138K as of Q1 2026.
MetLife Investment Management bought 16,362 Perspective Therapeutics shares in Q1 2026, an estimated $69.1K.
Perspective Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2395 holding.
MetLife Investment Management first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 8 quarters since.
MetLife Investment Management's Perspective Therapeutics position peaked at $416K in Q3 2024.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.